1371. Bretylium Tosylate

Nomenclature

CAS number: 61-75-6
2-Bromo-N-ethyl-N,N-dimethylbenzenemethanaminium salt with 4-methylbenzenesulfonic acid (1:1); (o-bromobenzyl)ethyldimethylammonium p-toluenesulfonate; N-ethyl-N-o-bromobenzyl-N,N-dimethylammonium tosylate; Bretylate (GSK); Bretylol (GSK).
C18H24BrNO3S; mol wt 414.36.
C 52.18%, H 5.84%, Br 19.28%, N 3.38%, O 11.58%, S 7.74%.

Description and references

Prepn: Copp, Stephenson, US 3038004 (1962 to Burroughs Wellcome). Metabolism: R. Kuntzman et al., Clin. Pharmacol. Ther. 11, 829 (1970). Toxicity study: E. I. Goldenthal, Toxicol. Appl. Pharmacol. 18, 185 (1971). Review of pharmacology: R. H. Heissenbuttel, J. T. Bigger, Ann. Intern. Med. 91, 229-238 (1979); R. J. Lee et al., in Pharmacological and Biochemical Properties of Drug Substances vol. 2, M. E. Goldberg, Ed. (Am. Pharm. Assoc., Washington, DC, 1979) pp 148-164. Comprehensive description: J. E. Carter et al., Anal. Profiles Drug Subs. 9, 71-86 (1980).

Chemical structure

Properties

Crystalline powder, mp 97-99°. Extremely bitter taste. uv max: 278, 271, 264 nm. Freely sol in water, methanol, ethanol. Practically insol in ether, ethyl acetate, hexane. LD50 in mice (mg/kg): 400 orally; 250 i.m. (Goldenthal).

Therapeutic Category

Antiadrenergic; antiarrhythmic (class III).

Keywords

Antiarrhythmic